SINTX Technologies Acquires SiNAPTIC Surgical Assets and IP to Expand into $1.3B Foot and Ankle Fusion Market
SINTX Technologies (NASDAQ: SINT) has announced the acquisition of SiNAPTIC Holdings' surgical business assets, marking a strategic move into the $1.3B foot and ankle fusion market. The deal includes six differentiated foot and ankle implant systems, complete with intellectual property and product designs.
The transaction, valued at $750,000 in common shares at $3.465 per share, includes 325,000 performance-based warrants. Key SiNAPTIC executives will join SINTX's leadership team, bringing expertise in product development, regulatory strategy, and commercialization. The global ankle fusion market is projected to grow from $750.5M to $1.38B by 2032, with a 9.1% CAGR.
SINTX Technologies (NASDAQ: SINT) ha annunciato l'acquisizione degli asset del settore chirurgico di SiNAPTIC Holdings, segnando una mossa strategica nel mercato da 1,3 miliardi di dollari per la fusione di piede e caviglia. L'accordo comprende sei sistemi differenziati di impianti per piede e caviglia, completi di proprietà intellettuale e progetti di prodotto.
La transazione, valutata in 750.000 dollari in azioni ordinarie a 3,465 dollari per azione, include 325.000 warrant basati sulle performance. I principali dirigenti di SiNAPTIC entreranno a far parte del team di leadership di SINTX, apportando competenze nello sviluppo prodotto, strategia regolatoria e commercializzazione. Il mercato globale della fusione della caviglia è previsto in crescita da 750,5 milioni di dollari a 1,38 miliardi entro il 2032, con un CAGR del 9,1%.
SINTX Technologies (NASDAQ: SINT) ha anunciado la adquisición de los activos del negocio quirúrgico de SiNAPTIC Holdings, marcando un movimiento estratégico hacia el mercado de fusión de pie y tobillo valorado en 1.3 mil millones de dólares. El acuerdo incluye seis sistemas diferenciados de implantes para pie y tobillo, junto con la propiedad intelectual y los diseños de productos.
La transacción, valorada en 750,000 dólares en acciones comunes a 3.465 dólares por acción, incluye 325,000 garantías basadas en el rendimiento. Los principales ejecutivos de SiNAPTIC se unirán al equipo directivo de SINTX, aportando experiencia en desarrollo de productos, estrategia regulatoria y comercialización. Se proyecta que el mercado global de fusión de tobillo crezca de 750.5 millones a 1.38 mil millones de dólares para 2032, con una tasa compuesta anual del 9.1%.
SINTX Technologies (NASDAQ: SINT)가 SiNAPTIC Holdings의 외과 사업 자산을 인수하며 13억 달러 규모의 발 및 발목 융합 시장에 전략적으로 진출했다고 발표했습니다. 이번 거래에는 지적 재산권과 제품 설계가 포함된 여섯 가지 차별화된 발 및 발목 임플란트 시스템이 포함되어 있습니다.
이번 거래는 주당 3.465달러에 보통주 75만 달러 상당과 325,000건의 성과 기반 워런트를 포함하며, 주요 SiNAPTIC 임원들이 SINTX 경영진에 합류하여 제품 개발, 규제 전략 및 상업화 분야의 전문 지식을 제공합니다. 전 세계 발목 융합 시장은 7억 5,050만 달러에서 2032년까지 13억 8천만 달러로 성장할 것으로 예상되며, 연평균 성장률은 9.1%입니다.
SINTX Technologies (NASDAQ : SINT) a annoncé l'acquisition des actifs de l'activité chirurgicale de SiNAPTIC Holdings, marquant une avancée stratégique sur le marché de la fusion du pied et de la cheville, évalué à 1,3 milliard de dollars. L'accord comprend six systèmes d'implants différenciés pour le pied et la cheville, incluant la propriété intellectuelle et les designs de produits.
La transaction, valorisée à 750 000 dollars en actions ordinaires au prix de 3,465 dollars par action, comprend 325 000 bons de souscription conditionnés à la performance. Les principaux cadres de SiNAPTIC rejoindront l'équipe dirigeante de SINTX, apportant leur expertise en développement produit, stratégie réglementaire et commercialisation. Le marché mondial de la fusion de la cheville devrait croître de 750,5 millions à 1,38 milliard de dollars d'ici 2032, avec un taux de croissance annuel composé (CAGR) de 9,1 %.
SINTX Technologies (NASDAQ: SINT) hat die Übernahme der chirurgischen Geschäftsvermögenswerte von SiNAPTIC Holdings bekannt gegeben und damit einen strategischen Schritt in den 1,3 Milliarden Dollar schweren Markt für Fuß- und Sprunggelenksfusionen gemacht. Der Deal umfasst sechs differenzierte Implantatsysteme für Fuß und Sprunggelenk, einschließlich geistigem Eigentum und Produktdesigns.
Die Transaktion hat einen Wert von 750.000 US-Dollar in Stammaktien zu je 3,465 US-Dollar und beinhaltet 325.000 leistungsabhängige Warrants. Schlüsselpersonen von SiNAPTIC werden dem Führungsteam von SINTX beitreten und bringen Fachwissen in Produktentwicklung, regulatorischer Strategie und Kommerzialisierung mit. Der globale Markt für Sprunggelenksfusionen wird voraussichtlich von 750,5 Millionen auf 1,38 Milliarden US-Dollar bis 2032 wachsen, bei einer durchschnittlichen jährlichen Wachstumsrate (CAGR) von 9,1 %.
- Acquisition of six FDA-reviewed foot and ankle implant systems accelerates path to commercialization
- Strategic entry into growing ankle fusion market with 9.1% CAGR
- Addition of experienced executive team and clinical expertise
- Existing FDA clearances and Master Files to streamline regulatory approvals
- Performance-based structure of deal aligns with shareholder interests
- Share dilution through issuance of $750,000 in common shares
- Additional potential dilution from 325,000 performance warrants
- Integration risks with new team and technology
Insights
SINTX's acquisition of SiNAPTIC assets strategically positions it to generate revenue in the high-growth foot and ankle fusion market.
SINTX Technologies has made a strategic acquisition of SiNAPTIC Holdings' surgical business assets, positioning itself for entry into the $750.5 million global ankle fusion market. This transaction represents a pivotal shift in SINTX's business trajectory, transitioning from R&D-focused operations toward commercial revenue generation.
The acquisition includes intellectual property and development assets for six differentiated foot and ankle implant systems with completed clinical development and mechanical testing. Crucially, a 510(k) pre-submission is already in place, which should significantly accelerate the regulatory pathway to market.
What makes this deal particularly valuable is the timing – SINTX is entering a market projected to reach $1.38 billion by 2032, representing a 9.1% CAGR. This growth rate substantially outpaces many medical device segments, indicating strong clinical demand and adoption potential.
The $750,000 acquisition cost, paid in common shares at a 10% premium, appears relatively modest considering the included assets and growth potential. The structure includes performance-based warrants tied to FDA clearance and revenue targets, aligning incentives between the companies.
Beyond the tangible assets, SINTX gains an experienced executive team with specialized expertise in product development, regulatory strategy, and commercialization – precisely the capabilities needed to monetize both the newly acquired and existing product portfolios. The formation of a Clinical Advisory Board under Dr. Scheer should enhance surgeon engagement, a critical factor for adoption in the orthopedic implant market.
This transaction effectively consolidates silicon nitride ceramic technology in the orthopedic space by acquiring a potential competitor, strengthening SINTX's market position while expanding its commercial opportunities in a growing segment of orthopedic surgery.
Strategic Acquisition Brings Patented Implant Designs, Seasoned Executive Team, and Near-Term Commercial Opportunities
SALT LAKE CITY, Utah, June 24, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics company focused on medical device innovation, today announced that it has executed a Definitive Agreement to acquire the surgical business assets of SiNAPTIC Holdings, LLC, a privately held company focused on silicon nitride ceramic manufacturing and innovation. This transaction is a significant milestone in SINTX’s strategy to acquire a potential competitor and drive commercial revenue growth and expand its product portfolio in the foot and ankle fusion market.
Under the terms of the agreement, SINTX has acquired all intellectual property, product designs, and development assets related to six (6) differentiated foot and ankle implant systems. These designs are backed by clinical development and mechanical testing and a 510(k) pre-submission that is expected to accelerate near-term commercial launch activities. The global ankle fusion market, currently valued at approximately
“This acquisition is transformative for SINTX by adding a family of FDA-reviewed implants, portfolio of new technologies, and capital, accelerating our shift from R&D to revenue generation and commercial scale,” said Eric Olson, CEO of SINTX Technologies. “Additionally, the SiNAPTIC team brings deep expertise in product development, regulatory strategy, and commercialization to support our existing commercial product portfolio—key elements in driving increased value for our shareholders.”
As part of the transaction, key members of the SiNAPTIC Surgical executive team and board of directors will join SINTX in the following roles:
- Chairman of SINTX Clinical Advisory Board, Bryan Scheer, M.D.
- Managing Director of Business Development, Hugh Roberts
- Chief Commercial Officer, Lisa Marie Del Re, MPE, ATC, NASM-PES
- Senior Vice President of Regulatory and Quality Affairs, Brian Hockett
- Senior Design Engineer, Basil Tharu, M.S.
In consideration for the acquired assets, SINTX issued
SINTX will manufacture all devices under its FDA-registered and ISO-certified quality system and leverage existing FDA clearances and Master Files to streamline regulatory approvals.
In addition, Dr. Bryan Scheer, Chairman and CEO of SiNAPTIC, will lead a newly formed Clinical Advisory Board to guide ongoing product development and surgeon engagement.
“This acquisition reflects our shared belief in the transformative potential of silicon nitride ceramic-enhanced implants and the strength of our combined teams,” said Dr. Scheer. “Together, we can accelerate the development of disruptive products and deliver meaningful clinical value.”
For more information, visit www.sintx.com.
About SINTX Technologies, Inc.
Located in Salt Lake City, Utah, SINTX Technologies is an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and agribiotech applications. SINTX is a global leader in the research, development, and manufacturing of silicon nitride, and its products have been implanted in humans since 2008. Over the past several years, SINTX has utilized strategic acquisitions and alliances to enter new markets. For more information on SINTX Technologies or its materials platform, visit www.sintx.com.
About SiNAPTIC
From industry to medical, SiNAPTIC is dedicated to the development and on-demand manufacturing of additive manufactured technical ceramics to improve lives and inspire the world to see in new ways. With a focus on innovation and quality, we offer a wide range of ceramic materials, allowing us to accelerate various applications across multiple industries such as aerospace & defense, medical, semiconductors, transportation, electronics, industrial manufacturing, and more. SiNAPTIC is based outside of Denver, Colorado. We transform ideas into real possibilities with our additive manufacturing platforms. Contact us to learn more about our services and how our technologies are driving the industry forward. For additional information, please visit www.sinaptic.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (“PSLRA”) that are subject to a number of risks and uncertainties. Forward-looking statements can be identified by words such as: "anticipate," "believe," "project," "estimate," "expect," "strategy,” "future," "likely," "may," "should," "will" and similar references to future periods.
Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations and beliefs. Forward looking statements include our belief that the acquisition will successfully shift our focus from R&D to revenue generation and commercial scale and result in increased value for our shareholders and accelerate the development of disruptive products and deliver meaningful clinical value. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, difficulty in commercializing ceramic technologies and development of new product opportunities. A discussion of other risks and uncertainties that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements can be found in SINTX’s Risk Factors disclosure in its Annual Report on Form 10-K, filed with the SEC on March 19, 2025, and in SINTX’s other filings with the SEC. SINTX undertakes no obligation to publicly revise or update the forward-looking statements to reflect events or circumstances that arise after the date of this report, except as required by law.
Business and Media Inquiries for SINTX:
SINTX Technologies, Inc.
801.839.3502
IR@sintx.com
FAQ
What did SINTX Technologies (SINT) acquire from SiNAPTIC Holdings?
How much did SINTX pay for the SiNAPTIC acquisition?
What is the market potential for SINTX's new ankle fusion products?
Who are the key executives joining SINTX from SiNAPTIC?
How will the SiNAPTIC acquisition impact SINTX's business strategy?
